Literature DB >> 9735419

Differential transferrin receptor density in human colorectal cancer: A potential probe for diagnosis and therapy.

A C Prost1, F Ménégaux, P Langlois, J M Vidal, M Koulibaly, J L Jost, J J Duron, J P Chigot, P Vayre, A Aurengo, J C Legrand, G Rosselin, C Gespach.   

Abstract

Transferrin receptor density was investigated in human colorectal surgical specimens. Crude membranes were prepared from 23 cancer tumors (adenocarcinoma or malignant villous tumor) and 3 non-cancer tumors (polyadenoma or villous tumor) and 26 adjacent control mucosa. Contrary to non-cancer tumors, Scatchard analysis of 125I-transferrin binding data evidenced higher maximal transferrin binding capacity and lower dissociation constant in cancer tissues (Bmax cancer 1.828+/-0.320 nmol/g, Kd 24.1+/-4.7 nM), as compared to paired control colonic mucosa (Bmax contol 0.851+/-0.182 nmol/g, Kd 30.7+/-7.3 nM), paired t-tests: Bmax p<0.001, Kd p<0.05). As the cancer/control Bmax ratio was 2.6+/-0.4,transferrin carrier constructs should be proposed for cancer imaging or therapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9735419     DOI: 10.3892/ijo.13.4.871

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  13 in total

1.  An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells.

Authors:  Patrick P Ng; Jay S Dela Cruz; David N Sorour; James M Stinebaugh; Seung-Uon Shin; Daniel S Shin; Sherie L Morrison; Manuel L Penichet
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-29       Impact factor: 11.205

2.  Automated selection of regions of interest for intensity-based FRET analysis of transferrin endocytic trafficking in normal vs. cancer cells.

Authors:  Ronak Talati; Andrew Vanderpoel; Amina Eladdadi; Kate Anderson; Ken Abe; Margarida Barroso
Journal:  Methods       Date:  2013-08-28       Impact factor: 3.608

3.  Surface-functionalized nanoparticles for targeted gene delivery across nasal respiratory epithelium.

Authors:  Sneha Sundaram; Shyamal K Roy; Balamurali K Ambati; Uday B Kompella
Journal:  FASEB J       Date:  2009-07-16       Impact factor: 5.191

Review 4.  Delivery of intracellular-acting biologics in pro-apoptotic therapies.

Authors:  Hongmei Li; Chris E Nelson; Brian C Evans; Craig L Duvall
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

5.  Molecular events contributing to cell death in malignant human hematopoietic cells elicited by an IgG3-avidin fusion protein targeting the transferrin receptor.

Authors:  Patrick P Ng; Gustavo Helguera; Tracy R Daniels; Simon Z Lomas; Jose A Rodriguez; Gary Schiller; Benjamin Bonavida; Sherie L Morrison; Manuel L Penichet
Journal:  Blood       Date:  2006-06-27       Impact factor: 22.113

Review 6.  Secreted proteins as a fundamental source for biomarker discovery.

Authors:  Miroslava Stastna; Jennifer E Van Eyk
Journal:  Proteomics       Date:  2012-01-19       Impact factor: 3.984

7.  Roles of hormone replacement therapy and iron in proliferation of breast epithelial cells with different estrogen and progesterone receptor status.

Authors:  Jisen Dai; Jinlong Jian; Maarten Bosland; Krystyna Frenkel; Güenther Bernhardt; Xi Huang
Journal:  Breast       Date:  2007-10-24       Impact factor: 4.380

Review 8.  Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.

Authors:  Phatsapong Yingchoncharoen; Danuta S Kalinowski; Des R Richardson
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

9.  Quantification of recombinant immunotoxin delivery to solid tumors allows for direct comparison of in vivo and in vitro results.

Authors:  Emily Mason-Osann; Kevin Hollevoet; Gerhard Niederfellner; Ira Pastan
Journal:  Sci Rep       Date:  2015-06-26       Impact factor: 4.379

Review 10.  Chiral nanomaterials for tumor therapy: autophagy, apoptosis, and photothermal ablation.

Authors:  Zaihui Peng; Long Yuan; Juncheng XuHong; Hao Tian; Yi Zhang; Jun Deng; Xiaowei Qi
Journal:  J Nanobiotechnology       Date:  2021-07-22       Impact factor: 10.435

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.